Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 18(6): 732-742, 2017 06.
Article
in En
| MEDLINE
| ID: mdl-28526536
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Antibodies, Monoclonal, Humanized
/
Maytansine
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Etiology_studies
/
Guideline
Limits:
Aged80
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2017
Type:
Article